Can a physician predict the clinical response to first-line immunomodulatory treatment in relapsing–remitting multiple sclerosis?
Zsolt Mezei,1 Daniel Bereczki,1,2 Lilla Racz,1 Laszlo Csiba,1 Tunde Csepany11Department of Neurology, University of Debrecen, Debrecen, Hungary; 2Department of Neurology, Semmelweis University, Budapest, HungaryBackground: Decreased relapse rate and slower disease progression have been reported with...
Guardado en:
Autores principales: | Mezei Z, Bereczki D, Racz L, Csiba L, Csepany T |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Dove Medical Press
2012
|
Materias: | |
Acceso en línea: | https://doaj.org/article/c27bafa17a504a3095bcb3740933dfa2 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Disease-modifying therapies in relapsing–remitting multiple sclerosis
por: Fabricio González-Andrade, et al.
Publicado: (2010) -
Risk-benefit considerations in the treatment of relapsing-remitting multiple sclerosis
por: Lugaresi A, et al.
Publicado: (2013) -
Disconnection of the hippocampus and amygdala associated with lesion load in relapsing–remitting multiple sclerosis: a structural and functional connectivity study
por: Zhou F, et al.
Publicado: (2015) -
Altered intra- and interregional synchronization in relapsing–remitting multiple sclerosis: a resting-state fMRI study
por: Wu L, et al.
Publicado: (2016) -
Potential short-term use of oral cladribine in treatment of relapsing-remitting multiple sclerosis
por: Julie A Murphy, et al.
Publicado: (2010)